{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T13:12:43Z","timestamp":1772802763281,"version":"3.50.1"},"reference-count":139,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","croh-online.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1016\/j.critrevonc.2018.06.016","type":"journal-article","created":{"date-parts":[[2018,6,23]],"date-time":"2018-06-23T16:30:34Z","timestamp":1529771434000},"page":"27-39","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":37,"special_numbering":"C","title":["Immune-checkpoint inhibitors in non-small cell lung cancer: A tool to improve patients\u2019 selection"],"prefix":"10.1016","volume":"129","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0764-3650","authenticated-orcid":false,"given":"Giuseppe Luigi","family":"Banna","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Passiglia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Colonese","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9442-2401","authenticated-orcid":false,"given":"Stefania","family":"Canova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica","family":"Menis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alfredo","family":"Addeo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Russo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7611-7369","authenticated-orcid":false,"given":"Diego Luigi","family":"Cortinovis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.critrevonc.2018.06.016_bib0005","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1111\/j.1572-0241.1999.00808.x","article-title":"Lamivudine therapy for chemotherapy-induced reactivation of hepatitis B virus infection","volume":"94","author":"Ahmed","year":"1999","journal-title":"Am. J. Gastroenterol."},{"issue":"12","key":"10.1016\/j.critrevonc.2018.06.016_bib0010","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1158\/2159-8290.CD-13-0310","article-title":"Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors","volume":"3","author":"Akbay","year":"2013","journal-title":"Cancer Discovery"},{"issue":"7463","key":"10.1016\/j.critrevonc.2018.06.016_bib0015","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nature12477","article-title":"Signatures of mutational processes in human cancer","volume":"500","author":"Alexandrov","year":"2013","journal-title":"Nature"},{"issue":"20","key":"10.1016\/j.critrevonc.2018.06.016_bib0020","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","article-title":"Durvalumab after chemoradiotherapy in stage III Non-small-cell lung cancer","volume":"377","author":"Antonia","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"Suppl. 15","key":"10.1016\/j.critrevonc.2018.06.016_bib0025","article-title":"Deleterious effect of baseline steroids on efficacy of PD-(L)1 blockade in patients with NSCLC","volume":"36","author":"Arbour","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2018.06.016_bib0030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.lungcan.2017.01.013","article-title":"Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer","volume":"106","author":"Bagley","year":"2017","journal-title":"Lung Cancer"},{"issue":"17","key":"10.1016\/j.critrevonc.2018.06.016_bib0035","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.2217\/fon.15.172","article-title":"How to develop novel treatments for EGFR-mutant lung cancer","volume":"11","author":"Banna","year":"2015","journal-title":"Future Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2018.06.016_bib0040","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1159\/000448005","article-title":"Predictive and prognostic value of early disease progression by PET evaluation in advanced non-small cell lung cancer","volume":"92","author":"Banna","year":"2017","journal-title":"Oncology"},{"issue":"7","key":"10.1016\/j.critrevonc.2018.06.016_bib0045","first-page":"3723","article-title":"Histology-based combination induction chemotherapy for elderly patients with clinical stage III Non-small cell lung cancer","volume":"37","author":"Banna","year":"2017","journal-title":"Anticancer Res."},{"key":"10.1016\/j.critrevonc.2018.06.016_bib0050","doi-asserted-by":"crossref","first-page":"603","DOI":"10.3389\/fphar.2017.00603","article-title":"Lactobacillus rhamnosus GG: an overview to explore the rationale of its use in cancer","volume":"8","author":"Banna","year":"2017","journal-title":"Front. Pharmacol."},{"issue":"6","key":"10.1016\/j.critrevonc.2018.06.016_bib0055","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/j.cell.2016.11.022","article-title":"Tumor interferon signaling regulates a multigenic resistance program to immune checkpoint blockade","volume":"167","author":"Benci","year":"2016","journal-title":"Cell"},{"issue":"8","key":"10.1016\/j.critrevonc.2018.06.016_bib0060","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1093\/neuonc\/nou307","article-title":"Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma","volume":"17","author":"Berghoff","year":"2015","journal-title":"Neuro-Oncology"},{"key":"10.1016\/j.critrevonc.2018.06.016_bib0065","first-page":"e116","article-title":"Immune checkpoint inhibitors in brain metastases: from biology to treatment","volume":"35","author":"Berghoff","year":"2016"},{"issue":"6286","key":"10.1016\/j.critrevonc.2018.06.016_bib0070","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1126\/science.aaf2834","article-title":"CANCER IMMUNOLOGY. The \"cancer immunogram\"","volume":"352","author":"Blank","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.critrevonc.2018.06.016_bib0075","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.36.15_suppl.9001","article-title":"Nivolumab (Nivo) + platinum-doublet Chemotherapy (chemo) vs chemo as first-line (1L) treatment (Tx) for advanced non-small cell lung cancer (NSCLC) with <1% tumor PD-L1 expression: results from CheckMate 227","volume":"36","author":"Borghaei","year":"2018","journal-title":"J. Clinical"},{"issue":"17","key":"10.1016\/j.critrevonc.2018.06.016_bib0080","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced nonsquamous Non-small-cell lung cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2018.06.016_bib0085","doi-asserted-by":"crossref","unstructured":"Borghaei, H., Brahmer, J., Horn, L., Ready, N., Steins, M., Felip, E., Paz-Ares, L., Xx, X., Barlesi, F., Antonia, S., Fayette, J., Rizvi, N., Crino, L., Reck, M., Erich Eberhardt, W.E., Hellmann, M., Desai, K., Li, A., Healey, D., Spigel, D., Mathias, C., P2.35: Nivolumab vs Docetaxel in Advanced NSCLC: CheckMate 017\/057 2-Y Update and Exploratory Cytokine Profile Analysis: Track: Immunotherapy Journal of Thoracic Oncology 11 (10), 2016, S237-S238.","DOI":"10.1016\/j.jtho.2016.08.106"},{"key":"10.1016\/j.critrevonc.2018.06.016_bib0090","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s40425-015-0064-2","article-title":"Rapid complete response of metastatic melanoma in a patient undergoing ipilimumab immunotherapy in the setting of active ulcerative colitis","volume":"3","author":"Bostwick","year":"2015","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.critrevonc.2018.06.016_bib0095","article-title":"Five-year follow-up from the CA209-003 study of nivolumab in previously treated advanced non-small cell lung cancer: clinical characteristics of long-term survivors Washington, DC [abstract CT077]","author":"Brahmer","year":"2017","journal-title":"American Association for Cancer Research Annual Meeting"},{"issue":"2","key":"10.1016\/j.critrevonc.2018.06.016_bib0100","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus docetaxel in advanced squamous-cell Non-small-cell lung cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.critrevonc.2018.06.016_bib0105","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.ctrv.2015.03.009","article-title":"Beyond EGFR and ALK inhibition: unravelling and exploiting novel genetic alterations in advanced non small-cell lung cancer","volume":"41","author":"Califano","year":"2015","journal-title":"Cancer Treat. Rev."},{"issue":"25","key":"10.1016\/j.critrevonc.2018.06.016_bib0110","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.1056\/NEJMoa1613493","article-title":"First-line nivolumab in stage IV or recurrent Non-small-cell lung cancer","volume":"376","author":"Carbone","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.critrevonc.2018.06.016_bib0115","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1158\/1078-0432.CCR-16-1741","article-title":"Hyperprogressive disease Is a New pattern of progression in cancer patients treated by anti-PD-1\/PD-L1","volume":"23","author":"Champiat","year":"2017","journal-title":"Clin. Cancer Res."},{"issue":"7637","key":"10.1016\/j.critrevonc.2018.06.016_bib0120","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/nature21349","article-title":"Elements of cancer immunity and the cancer-immune set point","volume":"541","author":"Chen","year":"2017","journal-title":"Nature"},{"issue":"3-4","key":"10.1016\/j.critrevonc.2018.06.016_bib0125","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.jaut.2009.09.008","article-title":"Recent insights in the epidemiology of autoimmune diseases: improved prevalence estimates and understanding of clustering of diseases","volume":"33","author":"Cooper","year":"2009","journal-title":"J. Autoimmun"},{"issue":"23","key":"10.1016\/j.critrevonc.2018.06.016_bib0130","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1056\/NEJMra0804752","article-title":"Immunologic aspects of chronic obstructive pulmonary disease","volume":"360","author":"Cosio","year":"2009","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.critrevonc.2018.06.016_bib0135","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/bjc.2014.555","article-title":"PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients","volume":"112","author":"D\u2019Incecco","year":"2015","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.critrevonc.2018.06.016_bib0140","article-title":"PD-1 blockade in advanced melanoma in patients with Hepatitis C and\/or HIV","volume":"2015","author":"Davar","year":"2015","journal-title":"Case Reports Oncol. Med."},{"issue":"1","key":"10.1016\/j.critrevonc.2018.06.016_bib0145","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/s12885-017-3122-y","article-title":"Relationships between longitudinal neutrophil to lymphocyte ratios, body weight changes, and overall survival in patients with non-small cell lung cancer","volume":"17","author":"Derman","year":"2017","journal-title":"BMC CAncer"},{"issue":"6_suppl","key":"10.1016\/j.critrevonc.2018.06.016_bib0150","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2017.35.6_suppl.462","article-title":"Impact of antibiotics on outcome in patients with metastatic renal cell carcinoma treated with immune checkpoint inhibitors","volume":"35","author":"Derosa","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2018.06.016_bib0155","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.lungcan.2017.07.024","article-title":"Neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab","volume":"111","author":"Diem","year":"2017","journal-title":"Lung Cancer"},{"key":"10.1016\/j.critrevonc.2018.06.016_bib0160","doi-asserted-by":"crossref","DOI":"10.1097\/QAD.0000000000001713","article-title":"Non-small cell lung cancer from HIV-infected patients expressed PD-L1 with marked inflammatory infiltrates","author":"Domblides","year":"2017","journal-title":"Aids"},{"issue":"12","key":"10.1016\/j.critrevonc.2018.06.016_bib0165","doi-asserted-by":"crossref","first-page":"3012","DOI":"10.1158\/1078-0432.CCR-16-2554","article-title":"Potential predictive value of TP53 and KRAS mutation Status for response to PD-1 blockade immunotherapy in lung adenocarcinoma","volume":"23","author":"Dong","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2018.06.016_bib0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2017.11.015","article-title":"Effectiveness and safety of nivolumab in advanced non-small cell lung cancer: the real-life data","author":"Dudnik","year":"2017","journal-title":"Lung Cancer"},{"issue":"7","key":"10.1016\/j.critrevonc.2018.06.016_bib0175","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1038\/ni1213","article-title":"A critical function for type I interferons in cancer immunoediting","volume":"6","author":"Dunn","year":"2005","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.critrevonc.2018.06.016_bib0180","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ctrv.2016.02.003","article-title":"Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy","volume":"45","author":"Eigentler","year":"2016","journal-title":"Cancer Treat. Rev."},{"issue":"10088","key":"10.1016\/j.critrevonc.2018.06.016_bib0185","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1016\/S0140-6736(17)31046-2","article-title":"Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1\/2 dose escalation and expansion trial","volume":"389","author":"El-Khoueiry","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.critrevonc.2018.06.016_bib0190","unstructured":"European Association for the Study of the Liver. Electronic address, e.e.e., European Association for the Study of the, L., 2017. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. Journal of hepatology 67(2), 370-398."},{"issue":"10030","key":"10.1016\/j.critrevonc.2018.06.016_bib0195","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1016\/S0140-6736(16)00587-0","article-title":"Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial","volume":"387","author":"Fehrenbacher","year":"2016","journal-title":"Lancet"},{"issue":"suppl_5","key":"10.1016\/j.critrevonc.2018.06.016_bib0200","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdx380.009","article-title":"1306PDHyperprogressive disease (HPD) is frequent in non-small cell lung cancer (NSCLC) patients (pts) treated with anti PD1\/PD-L1 monoclonal antibodies (IO)","volume":"28","author":"Ferrara","year":"2017","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2018.06.016_bib0205","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.ctrv.2017.08.003","article-title":"Immunosenescence and immunecheckpoint inhibitors in non-small cell lung cancer patients: does age really matter?","volume":"60","author":"Ferrara","year":"2017","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.critrevonc.2018.06.016_bib0210","series-title":"Diseases Proceedings of the 18th World Conference on Lung Cancer(P2.07)","first-page":"062a","article-title":"Single institutional experience of the use of PD-1 inhibitors to Non-small cell lung cancer patients with preexisting autoimmune","author":"Fossella","year":"2017"},{"key":"10.1016\/j.critrevonc.2018.06.016_bib0215","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1111\/j.1749-6632.2000.tb06651.x","article-title":"Inflamm-aging. An evolutionary perspective on immunosenescence","volume":"908","author":"Franceschi","year":"2000","journal-title":"Ann. N.Y. Acad. Sci."},{"issue":"4","key":"10.1016\/j.critrevonc.2018.06.016_bib0220","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/nrc3245","article-title":"The immune contexture in human tumours: impact on clinical outcome","volume":"12","author":"Fridman","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.critrevonc.2018.06.016_bib0225","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.lungcan.2017.06.008","article-title":"A pilot trial of nivolumab treatment for advanced non-small cell lung cancer patients with mild idiopathic interstitial pneumonia","volume":"111","author":"Fujimoto","year":"2017","journal-title":"Lung Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2018.06.016_bib0230","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1016\/j.jtho.2016.11.011","article-title":"PL04a.02: OAK, a randomized Ph III study of Atezolizumab vs docetaxel in patients with advanced NSCLC: results from subgroup analyses","volume":"12","author":"Gadgeel","year":"2017","journal-title":"J. Thorac. Oncol."},{"issue":"18","key":"10.1016\/j.critrevonc.2018.06.016_bib0235","doi-asserted-by":"crossref","first-page":"4585","DOI":"10.1158\/1078-0432.CCR-15-3101","article-title":"EGFR mutations and ALK rearrangements are associated with Low response rates to PD-1 pathway blockade in Non-small cell lung cancer: a retrospective analysis","volume":"22","author":"Gainor","year":"2016","journal-title":"Clin. Cancer Res."},{"issue":"Suppl. 5","key":"10.1016\/j.critrevonc.2018.06.016_bib0240","doi-asserted-by":"crossref","first-page":"v460","DOI":"10.1093\/annonc\/mdx380","article-title":"Blood-based biomarkers for cancer immunotherapy: tumor mutational burden in blood (bTMB) is associated with improved atezolizumab (atezo) efficacy in 2L1 NSCLC (POPLAR and OAK)","volume":"28","author":"Gandara","year":"2017","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2018.06.016_bib0245","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus chemotherapy in metastatic Non-small-cell lung cancer","author":"Gandhi","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2018.06.016_bib0250","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.critrevonc.2017.10.009","article-title":"Concomitant use of corticosteroids and immune checkpoint inhibitors in patients with hematologic or solid neoplasms: a systematic review","volume":"120","author":"Garant","year":"2017","journal-title":"Critical Reviews Oncology\/Hematology"},{"key":"10.1016\/j.critrevonc.2018.06.016_bib0255","doi-asserted-by":"crossref","unstructured":"Garassino, M., Rizvi, N., Besse, B., J\u00e4nne, P., Christoph, D., Peters, S., Toh, C.K., Kurata, T., Carcereny Costa, E., Koczywas, M., Felip, E., Chaft, J., Qiu, J., Kowanetz, M., Coleman, S., Mocci, S., Sandler, A., Gettinger, S., Johnson, M., OA03.02 Atezolizumab as 1L Therapy for Advanced NSCLC in PD-L1-Selected Patients: Updated ORR, PFS and OS Data from the BIRCH Study. Journal of Thoracic Oncology 12 (1), 2017, S251-S252.","DOI":"10.1016\/j.jtho.2016.11.239"},{"key":"10.1016\/j.critrevonc.2018.06.016_bib0260","doi-asserted-by":"crossref","unstructured":"Garassino, M., Vansteenkiste, J., Kim, J.-H., L\u00e9na, H., Mazi\u00e8res, J., Powderly, J., Dennis, P., Huang, Y., Wadsworth, C., Rizvi, N., PL04a.03: Durvalumab in \u22653rd-Line Locally Advanced or Metastatic, EGFR\/ALK Wild-Type NSCLC: Results from the Phase 2 ATLANTIC Study Journal of Thoracic Oncology 12 (1), 2017, S10-S11.","DOI":"10.1016\/j.jtho.2016.11.012"},{"key":"10.1016\/j.critrevonc.2018.06.016_bib0265","doi-asserted-by":"crossref","unstructured":"Gauvain, C., Vaul\u00e9on, E., Chouaid, C., Lerhun, E., Jabot, L., Scherpereel, A., Vinas, F., Cortot, A.B., Monnet, I., Intracerebral efficacy and tolerance of nivolumab in non-small-cell lung cancer patients with brain metastases. Lung cancer 116, 62-66.","DOI":"10.1016\/j.lungcan.2017.12.008"},{"issue":"7","key":"10.1016\/j.critrevonc.2018.06.016_bib0270","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/S1470-2045(16)30053-5","article-title":"Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial","volume":"17","author":"Goldberg","year":"2016","journal-title":"Lancet Oncol."},{"issue":"Suppl. 10","key":"10.1016\/j.critrevonc.2018.06.016_bib0275","doi-asserted-by":"crossref","first-page":"S238","DOI":"10.1016\/j.jtho.2016.08.107","article-title":"P2.36: nivolumab (nivo) in patients (pts) with advanced (adv) NSCLC and Central nervous system (CNS) metastases (mets): track: immunotherapy","volume":"11","author":"Goldman","year":"2016","journal-title":"J. Thorac. Oncol."},{"issue":"suppl. 6","key":"10.1016\/j.critrevonc.2018.06.016_bib0280","first-page":"vi359","article-title":"Efficacy and safety of nivolumab in elderly patients with advanced squamous NSCLC participating in the expanded access programme in Italy","volume":"27","author":"Grossi","year":"2016","journal-title":"Ann. Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2018.06.016_bib0285","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1093\/annonc\/mdx696","article-title":"Drastic decrease of the HIV reservoir in a patient treated with nivolumab for lung cancer","volume":"29","author":"Guihot","year":"2018","journal-title":"Ann. Oncol."},{"issue":"7","key":"10.1016\/j.critrevonc.2018.06.016_bib0290","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1093\/annonc\/mdx183","article-title":"Tumor immune microenvironment and nivolumab efficacy in EGFR mutation-positive non-small-cell lung cancer based on T790M status after disease progression during EGFR-TKI treatment","volume":"28","author":"Haratani","year":"2017","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2018.06.016_bib0295","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1801946","article-title":"Nivolumab plus ipilimumab in lung cancer with a High tumor mutational burden","author":"Hellmann","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"10.1016\/j.critrevonc.2018.06.016_bib0300","doi-asserted-by":"crossref","first-page":"2890","DOI":"10.1093\/annonc\/mdx321","article-title":"Nivolumab in HIV-related non-small-cell lung cancer","volume":"28","author":"Hentrich","year":"2017","journal-title":"Ann. Oncol."},{"issue":"10027","key":"10.1016\/j.critrevonc.2018.06.016_bib0305","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/S0140-6736(15)01281-7","article-title":"Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial","volume":"387","author":"Herbst","year":"2016","journal-title":"Lancet"},{"issue":"15_suppl","key":"10.1016\/j.critrevonc.2018.06.016_bib0310","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2016.34.15_suppl.3036","article-title":"Relationship of baseline tumoral ifn\u03b3 mRNA and PD-L1 protein expression to overall survival in durvalumab-treated NSCLC patients","volume":"34","author":"Higgs","year":"2016","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.critrevonc.2018.06.016_bib0315","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1097\/01.cji.0000177999.95831.7b","article-title":"Glucocorticoids do not inhibit antitumor activity of activated CD8+ T cells","volume":"28","author":"Hinrichs","year":"2005","journal-title":"J. Immunother."},{"issue":"4","key":"10.1016\/j.critrevonc.2018.06.016_bib0320","doi-asserted-by":"crossref","first-page":"447","DOI":"10.7326\/0003-4819-96-4-447","article-title":"Reactivation of chronic hepatitis B virus infection by cancer chemotherapy","volume":"96","author":"Hoofnagle","year":"1982","journal-title":"Ann. Intern. Med."},{"issue":"6086","key":"10.1016\/j.critrevonc.2018.06.016_bib0325","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1126\/science.1223490","article-title":"Interactions between the microbiota and the immune system","volume":"336","author":"Hooper","year":"2012","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.critrevonc.2018.06.016_bib0330","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.cell.2017.01.010","article-title":"Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma","volume":"168","author":"Hugo","year":"2017","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.critrevonc.2018.06.016_bib0335","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1001\/jamaoncol.2015.4368","article-title":"Ipilimumab therapy in patients with advanced melanoma and preexisting autoimmune disorders","volume":"2","author":"Johnson","year":"2016","journal-title":"JAMA Oncology"},{"key":"10.1016\/j.critrevonc.2018.06.016_bib0340","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.36.18_suppl.LBA9000","article-title":"IMpower131: primary PFS and safety analysis of a randomized phase III study of atezolizumab + carboplatin + paclitaxel or nab-paclitaxel vs carboplatin + nab-paclitaxel as 1L therapy in advanced squamous NSCLC","volume":"36","author":"Jotte","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.critrevonc.2018.06.016_bib0345","first-page":"3195","article-title":"Antibiotic use does not appear to influence response to nivolumab","volume":"37","author":"Kaderbhai","year":"2017","journal-title":"Anticancer Res."},{"issue":"5","key":"10.1016\/j.critrevonc.2018.06.016_bib0350","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/j.jtho.2017.01.005","article-title":"An immunogram for the cancer-immunity cycle: towards personalized immunotherapy of lung cancer","volume":"12","author":"Karasaki","year":"2017","journal-title":"J. Thorac. Oncol."},{"issue":"7","key":"10.1016\/j.critrevonc.2018.06.016_bib0355","doi-asserted-by":"crossref","first-page":"e96","DOI":"10.1016\/j.jtho.2017.03.008","article-title":"A case of a patient with idiopathic pulmonary fibrosis with lung squamous cell carcinoma treated with nivolumab","volume":"12","author":"Khunger","year":"2017","journal-title":"J. Thorac. Oncol."},{"issue":"29","key":"10.1016\/j.critrevonc.2018.06.016_bib0360","doi-asserted-by":"crossref","first-page":"48248","DOI":"10.18632\/oncotarget.17594","article-title":"Prognostic value of KRAS mutation in advanced non-small-cell lung cancer treated with immune checkpoint inhibitors: a meta-analysis and review","volume":"8","author":"Kim","year":"2017","journal-title":"Oncotarget"},{"issue":"54","key":"10.1016\/j.critrevonc.2018.06.016_bib0365","doi-asserted-by":"crossref","first-page":"93149","DOI":"10.18632\/oncotarget.18703","article-title":"Prognostic value of smoking status in non-small-cell lung cancer patients treated with immune checkpoint inhibitors: a meta-analysis","volume":"8","author":"Kim","year":"2017","journal-title":"Oncotarget"},{"issue":"1, Supplement","key":"10.1016\/j.critrevonc.2018.06.016_bib0370","doi-asserted-by":"crossref","first-page":"S432","DOI":"10.1016\/j.jtho.2016.11.503","article-title":"MA15.09 response to the treatment immediately before nivolumab monotherapy May predict clinical response to nivolumab","volume":"12","author":"Kobayashi","year":"2017","journal-title":"J. Thorac. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2018.06.016_bib0375","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s40425-014-0035-z","article-title":"Ipilimumab in patients with melanoma and autoimmune disease","volume":"2","author":"Kyi","year":"2014","journal-title":"J. For. Immunotherapy Cancer"},{"issue":"15","key":"10.1016\/j.critrevonc.2018.06.016_bib0380","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1097\/QAD.0000000000001599","article-title":"Hepatitis B reactivation in a long-term nonprogressor due to nivolumab therapy","volume":"31","author":"Lake","year":"2017","journal-title":"Aids"},{"issue":"6","key":"10.1016\/j.critrevonc.2018.06.016_bib0385","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.cllc.2014.07.002","article-title":"Activity of the EGFR-HER2 dual inhibitor afatinib in EGFR-mutant lung cancer patients with acquired resistance to reversible EGFR tyrosine kinase inhibitors","volume":"15","author":"Landi","year":"2014","journal-title":"Clin. Lung Cancer"},{"issue":"15_suppl","key":"10.1016\/j.critrevonc.2018.06.016_bib0390","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2017.35.15_suppl.e14523","article-title":"Immune response and adverse events to influenza vaccine in cancer patients undergoing PD-1 blockade","volume":"35","author":"Laubli","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2018.06.016_bib0395","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.jtho.2016.10.007","article-title":"Checkpoint inhibitors in metastatic EGFR-mutated Non-small cell lung cancer-a meta-analysis","volume":"12","author":"Lee","year":"2017","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.critrevonc.2018.06.016_bib0400","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2017.77.0305","article-title":"Safety of programmed death-1 pathway inhibitors among patients with non-small-cell lung cancer and preexisting autoimmune disorders","author":"Leonardi","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2018.06.016_bib0405","doi-asserted-by":"crossref","DOI":"10.1158\/2326-6066.CIR-17-0063","article-title":"Treatment-related adverse events predict improved clinical outcome in NSCLC patients on KEYNOTE-001 at a single center","author":"Lisberg","year":"2018","journal-title":"Cancer Immunology Res."},{"issue":"14","key":"10.1016\/j.critrevonc.2018.06.016_bib0410","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.89014","article-title":"Multiparametric profiling of non-small-cell lung cancers reveals distinct immunophenotypes","volume":"1","author":"Lizotte","year":"2016","journal-title":"JCI Insight"},{"issue":"3","key":"10.1016\/j.critrevonc.2018.06.016_bib0415","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1007\/s10549-011-1455-9","article-title":"A single-center, prospective and randomized controlled study: can the prophylactic use of lamivudine prevent hepatitis B virus reactivation in hepatitis B s-antigen seropositive breast cancer patients during chemotherapy?","volume":"127","author":"Long","year":"2011","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.critrevonc.2018.06.016_bib0420","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.36.18_suppl.LBA4","article-title":"Pembrolizumab (pembro) versus platinum-based chemotherapy (chemo) as first-line therapy for advanced\/metastatic NSCLC with a PD-L1 tumor proportion score (TPS) \u2265 1%: Open-label, phase 3 KEYNOTE-042 study","volume":"36","author":"Lopes","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"suppl_2","key":"10.1016\/j.critrevonc.2018.06.016_bib0425","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdx091.001","article-title":"81OSafety and efficacy analyses of atezolizumab in advanced non-small cell lung cancer (NSCLC) patients with or without baseline brain metastases","volume":"28","author":"Lukas","year":"2017","journal-title":"Ann. Oncol."},{"issue":"23","key":"10.1016\/j.critrevonc.2018.06.016_bib0430","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1056\/NEJMoa0802878","article-title":"Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B","volume":"359","author":"Marcellin","year":"2008","journal-title":"N. Engl. J. Med."},{"issue":"Suppl. (1)","key":"10.1016\/j.critrevonc.2018.06.016_bib0435","doi-asserted-by":"crossref","first-page":"S1328","DOI":"10.1016\/j.jtho.2016.11.1880","article-title":"P3.02c-084 predictive and prognostic clinical and pathological factors of nivolumab efficacy in Non-small-cell lung cancer (NSCLC) patients: topic: IT biomarkers","volume":"12","author":"Martin","year":"2017","journal-title":"J. Thorac. Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2018.06.016_bib0440","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1097\/CJI.0000000000000118","article-title":"Successful anti-PD-1 antibody treatment in a metastatic melanoma patient with known severe autoimmune disease","volume":"39","author":"Maul","year":"2016","journal-title":"J. Immunother."},{"issue":"6","key":"10.1016\/j.critrevonc.2018.06.016_bib0445","doi-asserted-by":"crossref","first-page":"E540","DOI":"10.21037\/jtd.2017.05.32","article-title":"Durable complete response to nivolumab in a patient with HIV and metastatic non-small cell lung cancer","volume":"9","author":"McCullar","year":"2017","journal-title":"J. Thorac. Dis."},{"issue":"6280","key":"10.1016\/j.critrevonc.2018.06.016_bib0450","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1126\/science.aaf1490","article-title":"Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade","volume":"351","author":"McGranahan","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.critrevonc.2018.06.016_bib0455","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ctrv.2017.05.005","article-title":"Prognostic role of pretreatment blood neutrophil-to-lymphocyte ratio in advanced cancer survivors: a systematic review and meta-analysis of 66 cohort studies","volume":"58","author":"Mei","year":"2017","journal-title":"Cancer Treat. Reviews"},{"issue":"2","key":"10.1016\/j.critrevonc.2018.06.016_bib0460","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1093\/annonc\/mdw443","article-title":"Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab","volume":"28","author":"Menzies","year":"2017","journal-title":"Ann. Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2018.06.016_bib0465","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1001\/jamaoncol.2017.4771","article-title":"Association of the lung immune prognostic index with immune checkpoint inhibitor outcomes in patients with advanced Non-small cell lung cancer","volume":"4","author":"Mezquita","year":"2018","journal-title":"JAMA ONcology"},{"issue":"7","key":"10.1016\/j.critrevonc.2018.06.016_bib0470","first-page":"3781","article-title":"Immunological Status May predict response to nivolumab in Non-small cell lung cancer without driver mutations","volume":"37","author":"Nakao","year":"2017","journal-title":"Anticancer Res."},{"key":"10.1016\/j.critrevonc.2018.06.016_bib0475","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/1756-9966-30-50","article-title":"Maintenance therapy in NSCLC: why? To whom? Which agent?","volume":"30","author":"Novello","year":"2011","journal-title":"J. Experimental & Clinical Cancer Res.: CR"},{"issue":"12","key":"10.1016\/j.critrevonc.2018.06.016_bib0480","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1016\/j.vaccine.2011.12.116","article-title":"Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity","volume":"30","author":"Ott","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.critrevonc.2018.06.016_bib0485","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.36.15_suppl.105","article-title":"Phase 3 study of carboplatin-paclitaxel\/nab-paclitaxel (Chemo) with or without Pembrolizumab (pembro) for patients (pts) with metastatic squamous (Sq) non-small cell lung cancer (NSCLC)","volume":"36","author":"Paz-Ares","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"12","key":"10.1016\/j.critrevonc.2018.06.016_bib0490","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1007\/s00262-014-1607-y","article-title":"Successful treatment with ipilimumab and interleukin-2 in two patients with metastatic melanoma and systemic autoimmune disease","volume":"63","author":"Pedersen","year":"2014","journal-title":"Cancer Immunology, Immunotherapy : CII"},{"key":"10.1016\/j.critrevonc.2018.06.016_bib0495","series-title":"2017 AACR Annual Meeting. Abstract CT082","article-title":"Impact of tumor mutation burden on the efficacy of first-line nivolumab in stage IV or recurrent non-small cell lung cancer: an exploratory analysis of CheckMate 026","author":"Peters","year":"2017"},{"key":"10.1016\/j.critrevonc.2018.06.016_bib0500","doi-asserted-by":"crossref","unstructured":"Peters, S., Cappuzzo, F., Horn, L., Paz-Ares, L., Borghaei, H., Barlesi, F., Steins, M., Felip, E., Spigel, D., Dorange, C., Lu, H., Healey, D., Kong Sanchez, T., Bhagavatheeswaran, P., J. Novotny Jr., Lestini, B., Brahmer, J., OA03.05 Analysis of Early Survival in Patients with Advanced Non-Squamous NSCLC Treated with Nivolumab vs Docetaxel in CheckMate 057. Journal of Thoracic Oncology 12 (1), 2017, S253.","DOI":"10.1016\/j.jtho.2016.11.241"},{"issue":"34","key":"10.1016\/j.critrevonc.2018.06.016_bib0505","doi-asserted-by":"crossref","first-page":"7824","DOI":"10.3748\/wjg.v22.i34.7824","article-title":"Global epidemiology of hepatitis C virus infection: an up-date of the distribution and circulation of hepatitis C virus genotypes","volume":"22","author":"Petruzziello","year":"2016","journal-title":"World J. Gastroenterol."},{"issue":"2","key":"10.1016\/j.critrevonc.2018.06.016_bib0510","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1002\/cncr.31043","article-title":"Comparison of the toxicity profile of PD-1 versus PD-L1 inhibitors in non-small cell lung cancer: a systematic analysis of the literature","volume":"124","author":"Pillai","year":"2018","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2018.06.016_bib0515","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1093\/annonc\/mdx642","article-title":"Safety of resuming anti-PD-1 in patients with immune-related adverse events (irAEs) during combined anti-CTLA-4 and anti-PD1 in metastatic melanoma","volume":"29","author":"Pollack","year":"2018","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2018.06.016_bib0520","doi-asserted-by":"crossref","unstructured":"Prat, A., Navarro, A., Pare, L., Reguart, N., Galvan, P., Pascual, T., Martinez, A., Nuciforo, P., Comerma, L., Alos, L., Pardo, N., Cedres, S., Fan, C., Parker, J.S., Gaba, L., Victoria, I., Vinolas, N., Vivancos, A., Arance, A., Felip, E., 2017. Immune-Related Gene Expression Profiling After PD-1 Blockade in Non-Small Cell Lung Carcinoma, Head and Neck Squamous Cell Carcinoma, and Melanoma. Cancer Research 77(13), 2017, 3540-3550.","DOI":"10.1158\/0008-5472.CAN-16-3556"},{"issue":"3","key":"10.1016\/j.critrevonc.2018.06.016_bib0525","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s11523-017-0495-4","article-title":"Immune checkpoint inhibitor-induced colitis: diagnosis and management","volume":"12","author":"Prieux-Klotz","year":"2017","journal-title":"Target. Oncol."},{"key":"10.1016\/j.critrevonc.2018.06.016_bib0530","author":"Ramalingam","year":"2018","journal-title":"Presented at the American Association for Cancer Research 2018 Annual Meeting"},{"issue":"19","key":"10.1016\/j.critrevonc.2018.06.016_bib0535","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1-positive Non-small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"10066","key":"10.1016\/j.critrevonc.2018.06.016_bib0540","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0140-6736(16)32517-X","article-title":"Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial","volume":"389","author":"Rittmeyer","year":"2017","journal-title":"Lancet"},{"issue":"6230","key":"10.1016\/j.critrevonc.2018.06.016_bib0545","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1126\/science.aaa1348","article-title":"Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer","volume":"348","author":"Rizvi","year":"2015","journal-title":"Science"},{"issue":"9","key":"10.1016\/j.critrevonc.2018.06.016_bib0550","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/0167-5699(93)90244-F","article-title":"Defining criteria for autoimmune diseases (witebsky\u2019s postulates revisited)","volume":"14","author":"Rose","year":"1993","journal-title":"Immunol. Today"},{"issue":"8","key":"10.1016\/j.critrevonc.2018.06.016_bib0555","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1093\/annonc\/mdx190","article-title":"Changes in serum interleukin-8 (IL-8) levels reflect and predict response to anti-PD-1 treatment in melanoma and non-small-cell lung cancer patients","volume":"28","author":"Sanmamed","year":"2017","journal-title":"Ann. Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2018.06.016_bib0560","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/dju435","article-title":"Objective measurement and clinical significance of TILs in non-small cell lung cancer","volume":"107","author":"Schalper","year":"2015","journal-title":"J. Natl. Cancer Inst."},{"issue":"2","key":"10.1016\/j.critrevonc.2018.06.016_bib0565","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1158\/2159-8290.CD-16-1223","article-title":"Primary resistance to PD-1 blockade mediated by JAK1\/2 mutations","volume":"7","author":"Shin","year":"2017","journal-title":"Cancer DIscovery"},{"issue":"1","key":"10.1016\/j.critrevonc.2018.06.016_bib0570","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1002\/cam4.1234","article-title":"Pretreatment advanced lung cancer inflammation index (ALI) for predicting early progression in nivolumab-treated patients with advanced non-small cell lung cancer","volume":"7","author":"Shiroyama","year":"2018","journal-title":"Cancer Med."},{"issue":"6264","key":"10.1016\/j.critrevonc.2018.06.016_bib0575","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1126\/science.aac4255","article-title":"Commensal bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy","volume":"350","author":"Sivan","year":"2015","journal-title":"Science"},{"issue":"24","key":"10.1016\/j.critrevonc.2018.06.016_bib0580","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1056\/NEJMoa1716948","article-title":"Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC","volume":"378","author":"Socinski","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"15_suppl","key":"10.1016\/j.critrevonc.2018.06.016_bib0585","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2016.34.15_suppl.9017","article-title":"Total mutation burden (TMB) in lung cancer (LC) and relationship with response to PD-1\/PD-L1 targeted therapies","volume":"34","author":"Spigel","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2018.06.016_bib0590","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.ejca.2017.07.033","article-title":"Baseline lymphopenia should not be used as exclusion criteria in early clinical trials investigating immune checkpoint blockers (PD-1\/PD-L1 inhibitors)","volume":"84","author":"Sun","year":"2017","journal-title":"European J. Cancer"},{"key":"10.1016\/j.critrevonc.2018.06.016_bib0595","article-title":"Evaluation of tumor mutation burden as a biomarker for immune checkpoint inhibitor efficacy: a calibration study of whole exome sequencing with FoundationOne Chicago, April 18, 2018","author":"Szustakowski","year":"2018","journal-title":"Program and Abstracts of the American Association for Cancer Research 2018 Annual Meeting"},{"issue":"4","key":"10.1016\/j.critrevonc.2018.06.016_bib0600","doi-asserted-by":"crossref","first-page":"660","DOI":"10.5306\/wjco.v5.i4.660","article-title":"Chronic obstructive pulmonary disease as a risk factor for lung cancer","volume":"5","author":"Takiguchi","year":"2014","journal-title":"World J. Clinical Oncology"},{"issue":"12","key":"10.1016\/j.critrevonc.2018.06.016_bib0605","doi-asserted-by":"crossref","first-page":"2962","DOI":"10.1093\/annonc\/mdx408","article-title":"Combined irradiation and targeted therapy or immune checkpoint blockade in brain metastases: toxicities and efficacy","volume":"28","author":"Tallet","year":"2017","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2018.06.016_bib0610","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.jtho.2017.10.030","article-title":"Peripheral blood biomarkers associated with clinical outcome in Non-small cell lung cancer patients treated with nivolumab","volume":"13","author":"Tanizaki","year":"2018","journal-title":"J. Thorac. Oncol."},{"issue":"7","key":"10.1016\/j.critrevonc.2018.06.016_bib0615","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1164\/rccm.200409-1275OC","article-title":"An animal model of autoimmune emphysema","volume":"171","author":"Taraseviciene-Stewart","year":"2005","journal-title":"Am. J. Resp. Crit. Care Med."},{"issue":"11","key":"10.1016\/j.critrevonc.2018.06.016_bib0620","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1158\/0008-5472.CAN-15-0255","article-title":"Classifying cancers based on T-cell infiltration and PD-L1","volume":"75","author":"Teng","year":"2015","journal-title":"Cancer Res."},{"issue":"6","key":"10.1016\/j.critrevonc.2018.06.016_bib0625","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1164\/rccm.201308-1483ST","article-title":"An official American thoracic society\/European respiratory society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias","volume":"188","author":"Travis","year":"2013","journal-title":"Am. J. Resp. Crit. Care Med."},{"issue":"7528","key":"10.1016\/j.critrevonc.2018.06.016_bib0630","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/nature13954","article-title":"PD-1 blockade induces responses by inhibiting adaptive immune resistance","volume":"515","author":"Tumeh","year":"2014","journal-title":"Nature"},{"issue":"6257","key":"10.1016\/j.critrevonc.2018.06.016_bib0635","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1126\/science.aad0095","article-title":"Genomic correlates of response to CTLA-4 blockade in metastatic melanoma","volume":"350","author":"Van Allen","year":"2015","journal-title":"Science"},{"issue":"6264","key":"10.1016\/j.critrevonc.2018.06.016_bib0640","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1126\/science.aad1329","article-title":"Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota","volume":"350","author":"Vetizou","year":"2015","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.critrevonc.2018.06.016_bib0645","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/cdd.2014.56","article-title":"Gut microbiome and anticancer immune response: really hot Sh*t!","volume":"22","author":"Viaud","year":"2015","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.critrevonc.2018.06.016_bib0650","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.ejca.2017.02.012","article-title":"Influenza vaccination in adult patients with solid tumours treated with chemotherapy","volume":"76","author":"Vollaard","year":"2017","journal-title":"Eur. J. Cancer"},{"issue":"Suppl 1","key":"10.1016\/j.critrevonc.2018.06.016_bib0655","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/jvh.12061","article-title":"PD-1\/PDL1 and CD28\/CD80 pathways modulate natural killer T cell function to inhibit hepatitis B virus replication","volume":"20","author":"Wang","year":"2013","journal-title":"J. Viral Hepat."},{"issue":"7","key":"10.1016\/j.critrevonc.2018.06.016_bib0660","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1200\/JCO.2015.66.1389","article-title":"Safety profile of nivolumab monotherapy: a pooled analysis of patients with advanced melanoma","volume":"35","author":"Weber","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"15_suppl","key":"10.1016\/j.critrevonc.2018.06.016_bib0665","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2017.35.15_suppl.3018","article-title":"FDA analysis of patients with baseline autoimmune diseases treated with PD-1\/PD-L1 immunotherapy agents","volume":"35","author":"Weinstock","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.critrevonc.2018.06.016_bib0670","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.it.2009.03.013","article-title":"CD28(-) T cells: their role in the age-associated decline of immune function","volume":"30","author":"Weng","year":"2009","journal-title":"Trends Immunol."},{"key":"10.1016\/j.critrevonc.2018.06.016_bib0675","doi-asserted-by":"crossref","DOI":"10.1038\/nri.2017.112","article-title":"Immune checkpoint blockade in infectious diseases","author":"Wykes","year":"2017","journal-title":"Nat. Rev. Immunol."},{"issue":"48-49","key":"10.1016\/j.critrevonc.2018.06.016_bib0680","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.jaut.2014.01.005","article-title":"Diagnosis and classification of drug-induced autoimmunity (DIA)","author":"Xiao","year":"2014","journal-title":"J. Autoimmun"},{"key":"10.1016\/j.critrevonc.2018.06.016_bib0685","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s12865-015-0103-2","article-title":"Dexamethasone enhances programmed cell death 1 (PD-1) expression during T cell activation: an insight into the optimum application of glucocorticoids in anti-cancer therapy","volume":"16","author":"Xing","year":"2015","journal-title":"BMC. Immunol."},{"issue":"3","key":"10.1016\/j.critrevonc.2018.06.016_bib0690","doi-asserted-by":"crossref","first-page":"498","DOI":"10.3892\/mco.2017.1342","article-title":"Value of neutrophil-to-lymphocyte ratio for predicting lung cancer prognosis: a meta-analysis of 7,219 patients","author":"Yu","year":"2017","journal-title":"Molecular Clinical Oncology 7"},{"issue":"9","key":"10.1016\/j.critrevonc.2018.06.016_bib0695","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1056\/NEJMoa1604958","article-title":"Mutations associated with acquired resistance to PD-1 blockade in melanoma","volume":"375","author":"Zaretsky","year":"2016","journal-title":"N. Engl. J. Med."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842818300866?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842818300866?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,11,4]],"date-time":"2020-11-04T06:11:52Z","timestamp":1604470312000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842818300866"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":139,"alternative-id":["S1040842818300866"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2018.06.016","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2018,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immune-checkpoint inhibitors in non-small cell lung cancer: A tool to improve patients\u2019 selection","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2018.06.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}